TIDMNSCI
NetScientific PLC
01 March 2016
NetScientific plc
Vortex BioSciences co-founder receives US Presidential award for
groundbreaking "Liquid Biopsy" technique
London, UK - 1 March 2016 - NetScientific plc ("NetScientific"
or the "Group", AIM: NSCI), the transatlantic biomedical and
healthcare technology group notes its operating subsidiary, Vortex
Biosciences' ('Vortex') announcement about its co-founder receiving
the US Presidential Early Career Award for Scientists and Engineers
(PECASE). The award is the highest honor bestowed by the United
States government for accomplishments in science and
engineering.
Professor Dino Di Carlo, co-founder and Chief Scientific Advisor
of Vortex, received the award for devising a first-of-its-kind
technique to quickly separate rare and information-rich circulating
tumor cells from common blood cells. This innovation has profound
implications for early diagnosis of cancer and precision medicine
development. Di Carlo's discovery is the underlying technology
behind Vortex BioSciences. The company was formed in 2012 to
commercialize the new technique for numerous applications, such as
diagnosis, treatment selection and monitoring, new compound
discovery and development and next generation sequencing.
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "Vortex is our lead diagnostics company
and we are delighted for Dino Di Carlo to have received this
outstanding recognition for his work. This further endorses
Vortex's core technology as we continue to accelerate its
development towards a potential best-in-class technology."
The full text of the announcement from Vortex can be found
below:
Contact Details
NetScientific
François R. Martelet, M.D., CEO Tel: +44 (0)20 3514 1800
Mark Nanovich, Interim CFO
Instinctif Partners
Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest Tel: +44 (0)20 7457 2020
Email: netscientific@instinctif.com
Vortex Biosciences Inventor Receives Presidential Award for
Research Leading to Groundbreaking "Liquid Biopsy" Technique
MENLO PARK, CA--March 1, 2016--President Obama has tapped Vortex
Biosciences co-founder and chief scientific advisor Professor Dino
Di Carlo as a recipient of the Presidential Early Career Awards for
Scientists and Engineers, the company announced today. Di Carlo
received the award for developing a fundamental approach to
manipulate cells within fluids, which has led to a
first-of-its-kind technique to quickly separate rare and
information-rich circulating tumor cells from common blood cells.
This innovation has profound implications for early diagnosis of
cancer and precision medicine development.
The award is the highest honor bestowed by the United States
government to scientists early in their careers.
"We couldn't be prouder to see Dino's dedication and innovation
recognized by a presidential administration that has issued such
bold challenges as calling for a cancer cure 'moonshot'," stated
Gene Walther, Vortex Biosciences CEO. "We believe his innovative
technology will enable far-reaching solutions for humanity."
Di Carlo's discovery underlies the technology behind Vortex
Biosciences, which was formed in 2012 to commercialize the new
technique for numerous applications, such as diagnosis, treatment
selection and monitoring, new compound discovery and development,
and next generation sequencing.
A pivotal moment for Di Carlo's innovation
In an age where diseases such as cancer, diabetes and a host of
chronic illnesses have become global epidemics, Di Carlo's
discovery transforms clinical research for diagnosis and treatment.
Di Carlo has pioneered a new field, "Inertial Microfluidics," that
directly disproves a long-held scientific belief that the momentum
of fluid was not significant or useful at very small scales. The
Vortex technology leverages these effects to capture live tumor
cells at high rates from blood in microscale "whirlpools."
Isolating live tumor cells from billions of other blood cells is
a task very much like the proverbial search for the needle in the
haystack. To diagnose disease and conduct other research
activities, clinicians and clinical researchers typically rely on
performing painful, disfiguring and sometimes even fatal biopsies,
with very mixed results.
Di Carlo's far less invasive process, referred to as a "liquid
biopsy," works at unprecedented speed and precision to find and
sort live tumor cells. Using the technique, clinical researchers
can vastly speed up and lower costs of disease diagnosis and
selection of therapies personalized to a patient.
"I'm particularly thankful to my team members whose valuable
contributions enabled my work," stated Professor Di Carlo. "It is
extremely rewarding to see the fundamental ideas and lab
experiments recognized by this award now translating to real-life
cell separation products by the team at Vortex Biosciences."
Di Carlo is Professor in the Department of Bioengineering at the
University of California, Los Angeles where he directs the
Microfluidic Biotechnology Laboratory. He is also Director of the
Jonsson Comprehensive Cancer Center - Cancer Nanotechnology Program
Area, and a member of the California NanoSystems Institute.
He has received numerous honors, including the U.S. National
Science Foundation Early CAREER Award, Office of Naval Research
Young Investigator Award, Packard Fellowship, Defense Advanced
Research Projects Agency Young Faculty Award, National Institutes
of Health Director's New Innovator Award, and the Coulter
Translational Research Award.
In addition to the Presidential Award, Di Carlo's work in
Inertial Microfluidics is also being honored by the American
Institute for Medical and Biological Engineering, which recently
announced his pending induction to its College of Fellows for
revolutionizing the biotechnology of cell separation.
###
About Vortex Biosciences Inc.
Vortex Biosciences is a cancer diagnostic instrument company
developing the Vortex VTX-1 bench top instrument, which runs a
simplified, high-speed blood test for a wide range of metastatic
cancers. The instrument harvests live circulating tumor cells from
patient blood samples for use in downstream clinical applications
such as monitoring disease progression and drug treatment
effectiveness. The Company will sell laboratory instruments along
with single use cartridges for each blood sample. For more
information, visit www.vortexbiosciences.com.
About NetScientific
NetScientific is the parent company of Vortex Biosciences, and a
biomedical and healthcare technology group that funds and develops
technologies that offer transformative benefits to society through
improved diagnosis, prognosis and treatment. Learn more at
www.netscientific.net.
Media Contact:
Stephanie Janard
Amendola Communications for Vortex Biosciences
sjanard@acmarketingpr.com
828-288-2831
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFLFBQXFLBBE
(END) Dow Jones Newswires
March 01, 2016 08:00 ET (13:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024